Intellia Therapeutics, Inc. (NTLA) stock analysis
NTLA · Intellia Therapeutics, Inc.
Latest recorded price: USD 9.86
Sector and industry: Healthcare · Biotechnology
Fiscal 2025 figures: revenue growth 9.1%, free cash flow margin -585.0%, ROIC -128.5%. The model flags 1 risk signal for this company (1 high severity).